1Casper ES,Kelsen DP,Alcock NW,et aL.IP cisplatin in patients with malignant ascites:pharmacokinetic evaluation and comparison with the iv route[].Cancer Treatment Reports.1983
2Markman M,Walker JI.Intraperitoneal Chemotherapy of Ovarian Cancer:A Review, With a Focus on Practical Aspects of Treatment[].Journal of Clinical Oncology.2006
3Howell SB.Pharmacologic principles of intraperitoneal chemotherapy for the treatment of ovarian cancer[].International Journal of Gynecological Cancer.2008
4Jemal A,Siegel R,Ward E,et al.Cancer statistics, 2008[].CA a Cancer Journal for Clinicians.2008
5Dedrick RL,Myers CE,Gungnay PM,et al.Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer[].Cancer Treatment Reports.1978
6Ozols RF,Bundy BN,Greer BE et al.Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study[].Journal of Clinical Oncology.2003
7Alberts DS,Liu PY,Hannigan EV,et al.Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer[].New England Journal of Medicine The.1996
8Mcgwire WP,Hoskins WJ,Brady MF,et al.Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer[].New England Journal of Homeopathy.1996
9Armstrong DK,Bundy B,Wenzel L,et al.Intraperitoneal cisplatin and paclitaxel in ovarian cancer[].New England Journal of Medicine The.2006
10Bristow RE.Predicting surgical outcome for advanced ovarian cancer, surgical standards of care, and the concept of kaizen[].Gynecologic Oncology.2009
4Hanauske AR, Chen V7 Paoletti P, Niyikiza C.Pemetrexed disodium: a novel antifolate clinicallyactive against multiple solid tumors. Oncologist2001; 6: 363-373.
5Bami S, Cabiddu M, Ghilardi M, Petrelli F. A novelperspective for an orphan problem: old and newdrugs for the medical management of malignantascites. Crit Rev Oncol Hematol 2011; 79:144-153.
6Markman M. Intraperitoneal antineoplastic drugdelivery: rationale and results. Lancet Oncol 2003; 4:277-283.
7Pestieau SR, Stuart OA, Sugarbaker PH. Multi-targeted antifolate (MTA): pharmacokinetics ofintraperitoneal administration in a rat model. Eur JSurg Oncol 2000; 26: 696-700.
8Bertino P, Piccardi F, Porta C, Favoni R, Cilli M,Mutti L, Gaudino G. Imatinib mesylate enhancestherapeutic effects of gemcitabine in human malig-nant mesothelioma xenografts. Clin Cancer Res 2008;14: 541-548.
9Ayantunde AA, Parsons SL. Pattern and prognosticfactors in patients with malignant ascites: a retro-spective study. Ann Oncol 2007; 18: 945-949.
10Dai H, Chen Y,. Elmquist WF. Distribution of thenovel antifolate pemetrexed to the brain. / Pharma-col Exp Ther 2005; 315: 222-229.
